A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma
Korean Journal of Hematology
;
: 188-191, 2005.
Article
in Korean
| WPRIM
| ID: wpr-720486
ABSTRACT
Thalidomide is an anti-angiogenic agent widely used in patients with multiple myeloma. The response to therapy is commonly monitored using serum and/or urine M protein, as these are known to reflect the tumor burden. Although extramedullary plasmacytomas are tissues with high neovascularization, it has been suggested in some reports that the response to thalidomide in these patients may be inferior, despite changes in the serum M protein level. Herein, we report the case of a patient who newly developed hepatosplenic extramedullary plasmacytoma, despite reduction in the serum M protein level following thalidomide treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasmacytoma
/
Thalidomide
/
Tumor Burden
/
Multiple Myeloma
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Hematology
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS